Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Royalty Pharma plc Director's Dealing 2025

Aug 8, 2025

30286_dirs_2025-08-08_f1c7612b-6f58-4204-a620-4d956b15274a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2025-08-06

Reporting Person: Coyne Terrance P. (EVP & CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-08-06 Class A Ordinary Shares A 3696 Acquired 52342 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-08-08 LP interests in RPI US Partners 2019, LP $ G 1000 Disposed Class A Ordinary Shares (10000) Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Class A Ordinary Shares 790000 Indirect
Class A Ordinary Shares 23270 Indirect
Class A Ordinary Shares 1500 Direct
Class A Ordinary Shares 24170 Indirect
Class A Ordinary Shares 1450 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
LP interests in RPI US Partners 2019, LP $0 Class A Ordinary Shares (4839420) 483942 Indirect
LP interests in RPI US Partners 2019, LP $0 Class A Ordinary Shares (1175260) 117526 Indirect

Footnotes

F1: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

F2: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.